The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Higuchi, T.
Right arrow Articles by Tsubata, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Higuchi, T.
Right arrow Articles by Tsubata, T.
The Journal of Immunology, 2002, 168: 9-12.
Copyright © 2002 by The American Association of Immunologists

Cutting Edge

Cutting Edge: Ectopic Expression of CD40 Ligand on B Cells Induces Lupus-Like Autoimmune Disease1

Tetsuya Higuchi*,{dagger}, Yuichi Aiba*, Takashi Nomura{ddagger}, Junichiro Matsuda§, Keiji Mochida§, Misao Suzuki, Hitoshi Kikutani||, Tasuku Honjo{ddagger}, Kiyoshi Nishioka{dagger} and Takeshi Tsubata2,*

* Department of Immunology, Medical Research Institute, and {dagger} Department of Dermatology, Faculty of Medicine, Tokyo Medical and Dental University, Tokyo, Japan; {ddagger} Department of Medical Chemistry, Faculty of Medicine, Kyoto University, Kyoto, Japan; § Department of Veterinary Science, National Institute of Infectious Diseases, Tokyo, Japan; Division of Transgenic Technology, Center for Animal Resources and Development, Kumamoto University, Kumamoto, Japan; and || Department of Molecular Immunology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
CD40 ligand (CD40L) is ectopically expressed on B cells in patients with systemic lupus erythematosus (SLE) and lupus-prone BXSB mice. To assess the role of the ectopic CD40L expression in development of SLE, we have established transgenic mice expressing CD40L on B cells. Some of the 12- to 14-mo-old CD40L-transgenic mice spontaneously produced autoantibodies such as antinuclear Abs, anti-DNA Abs, and antihistone Abs. Moreover, approximately half of the transgenic mice developed glomerulonephritis with immune-complex deposition, whereas the kidneys of the normal littermates showed either no pathological findings or only mild histological changes. These results indicate that CD40L on B cells causes lupus-like disease in the presence of yet unknown environmental factors that by themselves do not induce the disease. Thus, ectopic CD40L expression on B cells may play a crucial role in development of SLE.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Systemic lupus erythematosus (SLE)3 is a chronic autoimmune disease manifesting inflammatory damage in a variety of organs including glomerulonephritis (1, 2). The etiology of SLE involves both genetic and environmental factors (3), although the details are largely unknown. This disease is characterized by production of autoantibodies to various nuclear components (1, 2). Lupus-like disease is induced by abnormalities in either regulators of B cell Ag receptor signaling such as Lyn (4, 5, 6), Src homology domain 2-containing protein tyrosine phosphatase (7), and Fc{gamma}RIIB (8), or regulators of apoptosis such as Bim (9). However, none of the abnormalities of these molecules is shown so far in SLE patients.

CD40 is a member of the TNFR family and is expressed in cells such as B cells, macrophages, and dendritic cells (10, 11). Its ligand, CD40 ligand (CD40L), is a member of the TNF ligand family, expressed mainly on activated T cells. CD40/CD40L plays a pivotal role in cell activation. In B cells, interaction with CD40L promotes proliferation and survival of B cells, Ig isotype switching, and germinal center reaction (11). In patients with SLE, CD40L has been reported to be overexpressed on T cells and ectopically expressed on B cells (12, 13). Ectopic expression of CD40L on B cells is also observed in lupus-prone BXSB mice (14). Clegg et al. (15) have demonstrated that constitutive CD40L expression on T cells induces thymic atrophy due to enhanced apoptosis of thymocytes. They also showed inflammatory bowel disease and thickening of the glomerular capillary wall in the transgenic mice and suggested that these pathological changes may be due to abnormal T cell selection in thymus. However, autoantibody production or inflammatory changes in the glomeruli were not demonstrated in these mice.

We have established transgenic mouse lines expressing CD40L ectopically on B cells.4 At 8–12 wk of age, CD40L-transgenic mice show increase of both B cell number and serum Ig level by 2-fold and 5-fold, respectively. B cells are resistant to apoptosis induced in vitro, probably due to constitutive CD40 signaling in B cells. However, B cells are not spontaneously activated in these mice, because almost all the B cells are quiescent in vivo and show normal expression of surface markers for maturation and activation of B cells, such as IgD, IgM, CD23, and CD86. Remarkably, these mice show normal T cell development in thymus and exhibit only mild inflammatory bowel disease in contrast to the finding in transgenic mice expressing CD40L on T cells. In this study we demonstrate that CD40L-transgenic mice spontaneously produce autoantibodies such as anti-DNA Abs and develop lupus-like glomerulonephritis as they age. These findings indicate that ectopic expression of CD40L on B cells can induce lupus-like disease without inducing abnormal thymocyte development.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Mice

C57BL/6 and MRL/lpr mice were purchased from Sankyo Labo Service (Tokyo, Japan). CD40-deficient mice were described previously (16). The CD40L-transgenic mice were established by injecting the DNA fragment containing the mouse CD40L cDNA, a VH promoter, the IgH intron enhancer, and the Ig{kappa} 3' enhancer into C57BL/6 fertilized eggs. These mice were maintained in our animal facility. Cross-breeding of these mice was performed and the presence of each transgene was identified by tail DNA PCR assays.

Detection of antinuclear Ab

Cells of mouse myeloma line J558L were smeared on slide glass and fixed with 95% ethanol. After blocking with PBS containing BSA, sequentially diluted sera were applied and incubated for 1 h at room temperature. After washing, cells were reacted with FITC-conjugated anti-mouse IgG Ab (Southern Biotechnology Associates, Birmingham, AL) and observed under fluorescence microscopy.

ELISA analysis

Total amount of IgG was measured by standard sandwich ELISA analysis using anti-mouse IgG Ab (Southern Biotechnology Associates). For detection of autoantibodies, ssDNA was prepared by boiling solution containing bovine thymus DNA (Nacalai Tesque, Kyoto, Japan) for 5 min, followed by immersing on an ice bath. dsDNA was generated by sonicating grade I calf thymus DNA (Sigma-Aldrich, St. Louis, MO), followed by digestion with S1 nuclease. ELISA plates were coated with either 10 µg/ml ssDNA or the same concentration of histone type II-S from calf thymus (Sigma-Aldrich). Alternatively, ELISA plates were coated with 10 µg/ml dsDNA in the presence of poly L-lysine. Plates were blocked with PBS containing 0.5% BSA (Sigma-Aldrich), and sequentially diluted sera were incubated in plates. After further incubation with alkaline phosphatase-labeled anti-mouse IgG Ab (Southern Biotechnology Associates), plates were developed by phosphatase substrate (Sigma-Aldrich). The absorbance was measured by an ELISA reader (Molecular Devices, Menlo Park, CA) at 405 nm and analyzed with Delta Soft 3 (BioMetallics, Princeton, NJ). Concentrations of anti-DNA Abs were determined relative to the standard curves of anti-DNA mAb BW28-5 (IgG; a gift from Dr. S. Hirose, Juntendo University, Tokyo, Japan) reacting to both ssDNA and dsDNA.

Detection of proteinuria

The protein level of mouse urine was semiquantitatively analyzed as described previously (17).

Histopathological and immunohistochemical analysis

Mice were sacrificed and kidneys were perfused with saline. Each kidney was divided into two pieces. One piece was fixed in 10% formalin, paraffin-embedded, and sectioned before staining either with H&E or by periodic acid Schiff (PAS) procedure. The severity of glomerulonephritis was graded according to the degree of deposition of PAS-positive substance, hypercellularity, and sclerotic change in glomeruli as described previously (18, 19), with slight modification. The other piece of the kidney was quickly frozen in OCT compound (Sakura Finetechnical, Tokyo, Japan), sectioned, and stained with FITC-conjugated anti-mouse IgG Ab, anti-mouse IgM Ab, or anti-mouse C3 Ab (Southern Biotechnology Associates).

Statistics

The results were analyzed by nonparametoric Mann-Whitney’s U test.

Flow cytometry

Cells were stained with FITC-labeled anti-B220 mAb (BD PharMingen, San Diego, CA) and biotin-conjugated anti-mouse CD40L mAb (BD PharMingen), followed by reaction with PE-conjugated streptavidin (DAKO, Glostrup, Denmark). In some experiments, spleen cells were cultured with or without 10 µg/ml anti-CD40 mAb HM40-3 (a gift from Dr. H. Yagita, Juntendo University) for 12 h in RPMI 1640 medium supplemented with 10% FCS, 50 µM 2-ME, and 1 mM glutamine before staining.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
To assess autoantibody production in CD40L-transgenic mice, we obtained sera from 12- to 14-mo-old CD40L-transgenic mice and their nontransgenic littermates. The concentrations of total serum IgG in CD40L-transgenic mice and their normal littermates were 6.2 ± 2.16 and 3.2 ± 0.89 (mean ± SD of six mice), respectively. When we tested for IgG class antinuclear Abs, anti-DNA Abs, and antihistone Abs, all of which are frequently produced in SLE (1, 2), from one-third to one-half of CD40L-transgenic mice showed production of these autoantibodies (Fig. 1Go). In contrast, these autoantibodies were not produced in normal littermates except for a few mice producing a low level of the autoantibodies. In some CD40L-transgenic mice, the level of serum anti-DNA IgG was comparable to that in MRL/lpr mice used as positive controls. These results indicate that some of the CD40L-transgenic mice produce autoantibodies characteristic for SLE.



View larger version (22K):
[in this window]
[in a new window]
  		FIGURE 1. Spontaneous autoantibody production in CD40L-transgenic mice. Sera were obtained from 12- to 14-mo-old female CD40L-transgenic mice (CD40L Tg) and age-matched normal littermates (LM) maintained under conventional conditions. Sera from 4-mo-old female MRL/lpr mice were used as positive controls. A–C, IgG class antinuclear Abs were detected by indirect immunofluorescence. Titers of antinuclear Abs were determined by maximal fold dilution of sera that generate positive staining (A). Representative staining by sera from CD40L-transgenic mice (B) and sera from the normal littermates (C) are shown. D, Concentrations of IgG class anti-ssDNA Abs in sera were measured by ELISA. Horizontal bars represent mean values. E and F, Detection of IgG class anti-dsDNA Abs (E) and IgG class anti-histone Abs (F) by ELISA.

 
Because glomerulonephritis is often associated with SLE (1, 2), we next measured the urine protein level in 12- to 14-mo-old CD40L-transgenic mice and their normal littermates. The level of urine protein was elevated in some of the CD40L-transgenic mice (Fig. 2GoA), suggesting the presence of nephritis in these mice. Indeed, histopathological analysis revealed that approximately half of the CD40L-transgenic mice showed apparent glomerulonephritis with diffuse deposition of PAS-positive substance and hypercellularity in glomeruli (grade 2 and 3) (Fig. 2Go, B and C). Some of them were accompanied with sclerotic and/or severe proliferative changes (grade 3). In contrast, normal littermates showed either no pathological findings (grade 0) or only marginal changes (grade 1) (Fig. 2Go, B and D). We observed similar pathological changes in another line of CD40L-transgenic mice (data not shown). Immunofluorescence staining revealed deposition of IgG (Fig. 2GoE), C3 (Fig. 2GoF), and IgM (data not shown) in the glomeruli of CD40L-transgenic mice but not those of the normal littermates (Fig. 2Go, G and H). These results indicate that CD40L-transgenic mice spontaneously develop glomerulonephritis with immune-complex deposition, which is characteristic for SLE (20, 21, 22, 23).



View larger version (37K):
[in this window]
[in a new window]
  		FIGURE 2. CD40L-transgenic mice develop glomerulonephritis with immune-complex deposition. A, Semiquantitative measurement of urine protein. Urine from 12- to 14-mo-old female CD40L-transgenic mice (CD40L Tg) and age-matched normal littermates (LM) maintained under conventional conditions was spotted on filter paper. Protein level was measured semiquantitatively by staining with bromophenol blue. The grade of proteinuria was defined as follows: grade 6, equivalent to 30 mg/ml BSA; grade 5, 10 mg/ml BSA; grade 4, 3.3 mg/ml BSA; grade 3, 1.1 mg/ml BSA; grade 2, 0.37 mg/ml BSA; grade 1, 0.12 mg/ml BSA. B–D, Histopathological analysis of kidneys. Sections of kidneys from 12- to 14-mo-old CD40L-transgenic mice and age-matched normal littermates were stained with PAS or H&E and observed under microscopy. The severity of glomerulonephritis was graded from 0 to 3 according to the degree of deposition of PAS-positive substance, hypercellularity, and sclerosis in glomeruli (B). Representative histopathology of CD40L-transgenic glomeruli exhibiting severe proliferative glomerulonephritis (C) and glomeruli of normal littermates (D) are shown. E–H, Immunohistochemical analysis of kidneys. Frozen sections of kidneys from 12- to 14-mo-old CD40L-transgenic mice (E and F) and age-matched normal littermates (G and H) were stained with FITC-conjugated anti-mouse IgG Ab (E and G) or FITC-conjugated anti-mouse C3 Ab (F and H). Sections were observed under fluorescence microscopy. I and J, Detection of CD40L on B cells. CD40L-transgenic mice were crossed with CD40-deficient mice to generate CD40-/- CD40L-transgenic mice. Either freshly isolated spleen cells (I) or those treated with anti-CD40 Ab (J, thick line) or no Ab (J, dotted line) from indicated mice were stained with FITC-labeled anti-B220 Ab and biotin-labeled anti-CD40L Ab, followed by reaction with PE-labeled streptavidin. CD40LTg-CD40+/+, CD40L-transgenic mice; CD40LTg-CD40-/-, CD40-/- CD40L-transgenic mice; LM, normal littermates. Expression of CD40L on B220+ cells was analyzed by flow cytometry. Freshly isolated spleen cells (I) or anti-CD40 mAb- treated spleen cells (J) stained with FITC-labeled anti-B220 Ab and PE-labeled streptavidin were analyzed as staining controls (thin lines). Representative data of more than three experiments are shown.

 
Finally, we assessed CD40L expression on CD40L-transgenic B cells. We failed to detect CD40L expression on spleen B cells from CD40L-transgenic mice by flow cytometry, whereas CD40L expression was detectable on B cells from CD40-deficient CD40L-transgenic mice (Fig. 2GoI). This indicates that CD40L expression on B cells is down-modulated by interaction with CD40 in agreement with a previous observation (24). This conclusion is supported by the observation that CD40L expression become detectable by treatment with anti-CD40 mAb (Fig. 2GoJ), probably by blocking interaction between CD40 and CD40L. Thus, ectopic CD40L expression on B cells is not detectable, although it is crucial for inducing lupus-like disease.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
We demonstrate that approximately half to one-third of the transgenic mice expressing CD40L ectopically on B cells produce autoantibodies including anti-DNA Abs and exhibit glomerulonephritis with immune-complex deposition at 12–14 mo of age, indicating that some of the CD40L-transgenic mice develop lupus-like disease. Because not all the CD40L-transgenic mice develop lupus-like disease, CD40L expression appears to require environmental factors to induce lupus-like disease. Requirement of environmental factors is also suggested in development of SLE in human (3). Nonetheless, the normal littermates show either no abnormality or only mild histological changes in kidneys, although they are maintained in the same environment as CD40L-transgenic mice. These results indicate that ectopic expression of CD40L on B cells causes SLE-like disease in the presence of yet unknown environmental factors, which by themselves do not induce the disease. Thus, ectopic CD40L expression on B cells demonstrated in SLE patients (12) and SLE-prone BXSB mice (14) may be crucial in the pathogenesis of SLE. It will be interesting to systematically examine CD40L expression on B cells from a large number of SLE patients. In CD40L-transgenic mice, CD40L expression is not detected by flow cytometry due to its down-modulation in the presence of CD40 (24). Thus, a sensitive assay to detect CD40L is required for further analysis of CD40L expression on SLE B cells.

The total IgG level is markedly increased in young CD40L-transgenic mice compared with normal littermates.4 However, sera from 12- to 14-mo-old CD40L-transgenic mice contain only twice as much IgG as those from the normal littermates due to gradual increase of IgG in normal but not CD40L-transgenic mice as they age. Thus, the autoantibody production in CD40L-transgenic mice may not be ascribed to polyclonal B cell activation, but may involve abrogation of self-tolerance. Because CD40L blocks apoptosis of B cells induced by Ag receptor ligation (11), it might be possible that CD40L induces survival of self-reactive B cells, which otherwise undergo apoptosis by interaction with self-Ags.

Recent studies demonstrated that the serum level of BALL/TALL-1/BLyS, a member of TNF family activating the same signaling molecules that are activated by CD40L (25), is increased in patients with SLE (26, 27). As is the case for CD40L, overexpression of BALL/TALL-1/BlyS can induce autoantibody production and development of lupus-like disease in mice (28, 29). Moreover, inactivation of this molecule by soluble receptor blocks development of autoimmune disease in lupus-prone (New Zealand Black x New Zealand White)F1 mice (30), as is the case for inactivation of CD40L by treatment with anti-CD40L Ab (31). These findings suggest that BALL/TALL-1/BlyS as well as CD40L play a role in the pathogenesis of SLE. However, BALL/TALL-1/BLyS induces a marked increase in the B cell number (28, 29), which is not normally seen in SLE patients, whereas CD40L-transgenic mice show only 2-fold increase in B cell number.4 Moreover, the disease activity of SLE does not correlate with the level of BALL/TALL-1/BlyS (26). Further analysis is thus required for fully elucidating the role of CD40L and BALL/TALL-1/BLyS in the pathogenesis of SLE.


   Acknowledgments
 
We thank Dr. S. Hirose for reagents and initial pathological observations on CD40L-transgenic mice, Dr. H. Yagita for reagents, and S. Irie, C. Kawana, and M. Sekiya for technical help.


   Footnotes
 
1 This work was supported by grants from the Ministry of Education, Science, Sport and Culture, Ministry of Health and Welfare, the Program for Promotion of Fundamental Studies in Health Sciences of the Organization for Pharmaceutical Safety and Research of Japan, the Naito Foundation, Terumo Life Science Foundation, and the Mochida Memorial Foundation for Medical and Pharmaceutical Research. Back

2 Address correspondence and reprints requests to Dr. Takeshi Tsubata, Department of Immunology, Medical Research Institute, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan. E-mail address: tsubata.imm{at}mri.tmd.ac.jp Back

3 Abbreviations used in this paper: SLE, systemic lupus erythematosus; CD40L, CD40 ligand; PAS, periodic acid Schiff. Back

4 Y. Aiba, T. Higuchi, T. Nomura, J. Matsuda, K. Mochida, K. Furukawa, M. Suzuki, H. Kikutani, T. Tokuhisa, T. Takemori, T. Honjo, and T. Tsubata. CD40 signaling promotes maturation of germinal center B cells in vivo. Submitted for publication. Back

Received for publication September 21, 2001. Accepted for publication November 1, 2001.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Mills, J. A.. 1994. Systemic lupus erythematosus. N. Engl. J. Med. 330:1871.[Free Full Text]
  2. Kotzin, B. L.. 1996. Systemic lupus erythematosus. Cell 85:303.[Medline]
  3. Wakeland, E. K., A. E. Wandstrat, K. Liu, L. Morel. 1999. Genetic dissection of systemic lupus erythematosus. Curr. Opin. Immunol. 11:701.[Medline]
  4. Hibbs, M. L., D. M. Tarlinton, J. Armes, D. Grail, G. Hodgson, R. Maglitto, S. A. Stacker, A. R. Dunn. 1995. Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell 83:301.[Medline]
  5. Nishizumi, H., I. Taniuchi, Y. Yamanashi, D. Kitamura, D. Ilic, S. Mori, T. Watanabe, T. Yamamoto. 1995. Impaired proliferation of peripheral B cells and indication of autoimmune disease in lyn-deficient mice. Immunity 3:549.[Medline]
  6. Chan, V. W., F. Meng, P. Soriano, A. L. DeFranco, C. A. Lowell. 1997. Characterization of the B lymphocyte populations in Lyn-deficient mice and the role of Lyn in signal initiation and down-regulation. Immunity 7:69.[Medline]
  7. Shultz, L. D., P. A. Schweitzer, T. V. Rajan, T. Yi, J. N. Ihle, R. J. Matthews, M. L. Thomas, D. R. Beier. 1993. Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene. Cell 73:1445.[Medline]
  8. Bolland, S., J. V. Ravetch. 2000. Spontaneous autoimmune disease in Fc{gamma}RIIB-deficient mice results from strain-specific epistasis. Immunity 13:277.[Medline]
  9. Bouillet, P., D. Metcalf, D. C. Huang, D. M. Tarlinton, T. W. Kay, F. Kontgen, J. M. Adams, A. Strasser. 1999. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 286:1735.[Abstract/Free Full Text]
  10. van Kooten, C., J. Banchereau. 1997. Functions of CD40 on B cells, dendritic cells and other cells. Curr. Opin. Immunol 9:330.[Medline]
  11. Banchereau, J., F. Bazan, D. Blanchard, F. Briere, J. P. Galizzi, C. van Kooten, Y. J. Liu, F. Rousset, S. Saeland. 1994. The CD40 antigen and its ligand. Annu. Rev. Immunol. 12:881.[Medline]
  12. Desai-Mehta, A., L. Lu, R. Ramsey-Goldman, S. K. Datta. 1996. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J. Clin. Invest. 97:2063.[Medline]
  13. Koshy, M., D. Berger, M. K. Crow. 1996. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J. Clin. Invest. 98:826.[Medline]
  14. Blossom, S., E. B. Chu, W. O. Weigle, K. M. Gilbert. 1997. CD40 ligand expressed on B cells in the BXSB mouse model of systemic lupus erythematosus. J. Immunol. 159:4580.[Abstract]
  15. Clegg, C. H., J. T. Rulffes, H. S. Haugen, I. H. Hoggatt, A. Aruffo, S. K. Durham, A. G. Farr, D. Hollenbaugh. 1997. Thymus dysfunction and chronic inflammatory disease in gp39 transgenic mice. Int. Immunol. 9:1111.[Abstract/Free Full Text]
  16. Kawabe, T., T. Naka, K. Yoshida, T. Tanaka, H. Fujiwara, S. Suematsu, N. Yoshida, T. Kishimoto, H. Kikutani. 1994. The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity 1:167.[Medline]
  17. Knight, J. G., D. D. Adams, H. D. Purves. 1977. The genetic contribution of the NZB mouse to the renal disease of the NZB x NZW hybrid. Clin. Exp. Immunol. 28:352.[Medline]
  18. Botto, M., C. Dell’Agnola, A. E. Bygrave, E. M. Thompson, H. T. Cook, F. Petry, M. Loos, P. P. Pandolfi, M. J. Walport. 1998. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat. Genet. 19:56.[Medline]
  19. Napirei, M., H. Karsunky, B. Zevnik, H. Stephan, H. G. Mannherz, T. Moroy. 2000. Features of systemic lupus erythematosus in Dnase1-deficient mice. Nat. Genet. 25:177.[Medline]
  20. ter Borg, E. J., G. Horst, E. J. Hummel, P. C. Limburg, C. G. Kallenberg. 1990. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus: a long-term, prospective study. Arthritis Rheum. 33:634.[Medline]
  21. Esdaile, J. M., M. Abrahamowicz, L. Joseph, T. MacKenzie, Y. Li, D. Danoff. 1996. Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus: why some tests fail. Arthritis Rheum. 39:370.[Medline]
  22. Steinberg, A. D., M. F. Gourley, D. M. Klinman, G. C. Tsokos, D. E. Scott, A. M. Krieg. 1991. Systemic lupus erythematosus. Ann. Intern. Med. 115:548.
  23. Foster, M. H., V. R. Kelley. 1999. Lupus nephritis: update on pathogenesis and disease mechanisms. Semin. Nephrol. 19:173.[Medline]
  24. Yellin, M. J., K. Sippel, G. Inghirami, L. R. Covey, J. J. Lee, J. Sinning, E. A. Clark, L. Chess, S. Lederman. 1994. CD40 molecules induce down-modulation and endocytosis of T cell surface T cell-B cell activating molecule/CD40L: potential role in regulating helper effector function. J. Immunol. 152:598.[Abstract]
  25. Do, R. K., E. Hatada, H. Lee, M. R. Tourrigny, D. Hilbert, S. Chen-Kiang. 2000. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J. Exp. Med. 192:953.[Abstract/Free Full Text]
  26. Zhang, J., V. Roschke, K. P. Baker, Z. Wang, G. S. Alarcon, B. J. Fessler, H. Bastian, R. P. Kimberly, T. Zhou. 2001. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J. Immunol. 166:6.[Abstract/Free Full Text]
  27. Cheema, G. S., V. Roschke, D. M. Hilbert, W. Stohl. 2001. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 44:1313.[Medline]
  28. Mackay, F., S. A. Woodcock, P. Lawton, C. Ambrose, M. Baetscher, P. Schneider, J. Tschopp, J. L. Browning. 1999. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J. Exp. Med. 190:1697.[Abstract/Free Full Text]
  29. Khare, S. D., I. Sarosi, X. Z. Xia, S. McCabe, K. Miner, I. Solovyev, N. Hawkins, M. Kelley, D. Chang, G. Van, et al 2000. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc. Natl. Acad. Sci. USA 97:3370.[Abstract/Free Full Text]
  30. Gross, J. A., J. Johnston, S. Mudri, R. Enselman, S. R. Dillon, K. Madden, W. Xu, J. Parrish-Novak, D. Foster, C. Lofton-Day, et al 2000. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404:995.[Medline]
  31. Early, G. S., W. Zhao, C. M. Burns. 1996. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand Black x New Zealand White mice: response correlates with the absence of an anti-antibody response. J. Immunol. 157:3159.[Abstract]



This article has been cited by other articles:


Home page
 J. Exp. Med.Home page
R. J. Brownlie, K. E. Lawlor, H. A. Niederer, A. J. Cutler, Z. Xiang, M. R. Clatworthy, R. A. Floto, D. R. Greaves, P. A. Lyons, and K. G.C. Smith
Distinct cell-specific control of autoimmunity and infection by Fc{gamma}RIIb
J. Exp. Med., April 14, 2008; 205(4): 883 - 895.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Q. Lu, A. Wu, L. Tesmer, D. Ray, N. Yousif, and B. Richardson
Demethylation of CD40LG on the Inactive X in T Cells from Women with Lupus
J. Immunol., November 1, 2007; 179(9): 6352 - 6358.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. Toyoda, R. Nagae, M. Akagawa, K. Ishino, T. Shibata, S. Ito, N. Shibata, T. Yamamoto, M. Kobayashi, Y. Takasaki, et al.
Protein-bound 4-Hydroxy-2-nonenal: AN ENDOGENOUS TRIGGERING ANTIGEN OF ANTI-DNA RESPONSE
J. Biol. Chem., August 31, 2007; 282(35): 25769 - 25778.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
X Li, V Rider, B F Kimler, and N I Abdou
Estrogen does not regulate CD154 mRNA stability in systemic lupus erythematosus T cells
Lupus, December 1, 2006; 15(12): 852 - 857.
[Abstract] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. Akagawa, S. Ito, K. Toyoda, Y. Ishii, E. Tatsuda, T. Shibata, S. Yamaguchi, Y. Kawai, K. Ishino, Y. Kishi, et al.
Bispecific Abs against modified protein and DNA with oxidized lipids
PNAS, April 18, 2006; 103(16): 6160 - 6165.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L. V. Pham, A. T. Tamayo, L. C. Yoshimura, Y.-C. Lin-Lee, and R. J. Ford
Constitutive NF-{kappa}B and NFAT activation in aggressive B-cell lymphomas synergistically activates the CD154 gene and maintains lymphoma cell survival
Blood, December 1, 2005; 106(12): 3940 - 3947.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
E. M. Jacobson, E. Concepcion, T. Oashi, and Y. Tomer
A Graves' Disease-Associated Kozak Sequence Single-Nucleotide Polymorphism Enhances the Efficiency of CD40 Gene Translation: A Case for Translational Pathophysiology
Endocrinology, June 1, 2005; 146(6): 2684 - 2691.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
D. Panagopoulos, P. Victoratos, M. Alexiou, G. Kollias, and G. Mosialos
Comparative Analysis of Signal Transduction by CD40 and the Epstein-Barr Virus Oncoprotein LMP1 In Vivo
J. Virol., December 1, 2004; 78(23): 13253 - 13261.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
D. Daoussis, A. P. Andonopoulos, and S.-N. C. Liossis
Targeting CD40L: a Promising Therapeutic Approach
Clin. Vaccine Immunol., July 1, 2004; 11(4): 635 - 641.
[Full Text]

Home page
 Sci SignalHome page
M. M. Harnett
CD40: A Growing Cytoplasmic Tale
Sci. Signal., June 15, 2004; 2004(237): pe25 - pe25.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. Kawamura, T. Kanai, T. Dohi, K. Uraushihara, T. Totsuka, R. Iiyama, C. Taneda, M. Yamazaki, T. Nakamura, T. Higuchi, et al.
Ectopic CD40 Ligand Expression on B Cells Triggers Intestinal Inflammation
J. Immunol., May 15, 2004; 172(10): 6388 - 6397.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
J Yazdany and J Davis
The role of CD40 ligand in systemic lupus erythematosus
Lupus, May 1, 2004; 13(5): 377 - 380.
[Abstract] [PDF]

Home page
 LupusHome page
P I Sidiropoulos and D T Boumpas
Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients
Lupus, May 1, 2004; 13(5): 391 - 397.
[Abstract] [PDF]

Home page
 Ann Rheum DisHome page
M J Citores, I Rua-Figueroa, C Rodriguez-Gallego, A Durantez, M I Garcia-Laorden, C Rodriguez-Lozano, J C Rodriguez-Perez, J A Vargas, and P Perez-Aciego
The dinucleotide repeat polymorphism in the 3'UTR of the CD154 gene has a functional role on protein expression and is associated with systemic lupus erythematosus
Ann Rheum Dis, March 1, 2004; 63(3): 310 - 317.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
H. Iwai, M. Abe, S. Hirose, F. Tsushima, K. Tezuka, H. Akiba, H. Yagita, K. Okumura, H. Kohsaka, N. Miyasaka, et al.
Involvement of Inducible Costimulator-B7 Homologous Protein Costimulatory Pathway in Murine Lupus Nephritis
J. Immunol., September 15, 2003; 171(6): 2848 - 2854.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
K.-I. Imadome, M. Shirakata, N. Shimizu, S. Nonoyama, and Y. Yamanashi
CD40 ligand is a critical effector of Epstein-Barr virus in host cell survival and transformation
PNAS, June 24, 2003; 100(13): 7836 - 7840.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Nakae, S. Saijo, R. Horai, K. Sudo, S. Mori, and Y. Iwakura
IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist
PNAS, May 13, 2003; 100(10): 5986 - 5990.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
C G Katsiari, S-N. Liossis, A M Dimopoulos, D V Charalambopoulos, M Mavrikakis, and P P Sfikakis
CD40L overexpression on T cells and monocytes from patients with systemic lupus erythematosus is resistant to calcineurin inhibition
Lupus, June 1, 2002; 11(6): 370 - 378.
[Abstract] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Higuchi, T.
Right arrow Articles by Tsubata, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Higuchi, T.
Right arrow Articles by Tsubata, T.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS